logo

Kiniksa Pharmaceuticals, Ltd. (KNSA)



Trade KNSA now with
  Date
  Headline
8/3/2022 7:54:54 AM Kiniksa Pharma Q2 Net Loss $20.0 Mln; Announces Global License Deal With Genentech For Vixarelimab
12/29/2021 4:21:38 PM Wedbush Is Raising Kiniksa Pharmaceuticals, Ltd. (KNSA) FY22 Estimate To -1.55 From -1.56
12/29/2021 4:21:14 PM Wedbush Is Increasing Kiniksa Pharmaceuticals, Ltd. (KNSA) FY21 Estimate To -2.26 From -2.27
12/29/2021 4:20:48 PM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $26 Price Target
12/28/2021 7:07:06 AM Kiniksa Says Phase 3 Trial Of Mavrilimumab In COVID-19-Related ARDS Fails To Meet Primary Endpoint
3/19/2019 7:33:29 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $30 Price Target
12/12/2018 6:51:51 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $33 Up From $31 Price Target
9/17/2018 6:38:51 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $31 Price Target
9/11/2018 9:50:12 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $31 Price Target
8/7/2018 8:03:19 AM Wedbush Is Raising Kiniksa Pharmaceuticals, Ltd. (KNSA) FY19 Estimate To -3.08 From -3.60
8/7/2018 8:03:05 AM Wedbush Is Increasing Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 19 Estimate To -0.87 From -1.01
8/7/2018 8:02:50 AM Wedbush Is Raising Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 19 Estimate To -0.80 From -0.93
8/7/2018 8:02:34 AM Wedbush Is Raising Kiniksa Pharmaceuticals, Ltd. (KNSA) Q2 19 Estimate To -0.74 From -0.86
8/7/2018 8:02:21 AM Wedbush Is Increasing Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 19 Estimate To -0.68 From -0.79
8/7/2018 8:02:00 AM Wedbush Is Cutting Kiniksa Pharmaceuticals, Ltd. (KNSA) FY18 Estimate To -2.71 From -2.43
8/7/2018 8:01:47 AM Wedbush Is Increasing Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 18 Estimate To -0.80 From -0.94
8/7/2018 8:01:32 AM Wedbush Is Increasing Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 18 Estimate To -0.45 From -0.52
8/7/2018 8:01:09 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $32 Price Target